cdm_source_name,cdm_source_abbreviation,cdm_holder,source_description,source_documentation_reference,cdm_etl_reference,source_release_date,cdm_release_date,cdm_version,vocabulary_version
Safety and Efficacy of the XanomelineTransdermal Therapeutic System (TTS) in Patients with Mild to Moderatealzheimer's disease.,NCT00987090,Clinical Trials Workgroup,"Safety and Efficacy of the XanomelineTransdermal Therapeutic System (TTS) in Patients with Mild to Moderatealzheimer's disease. Trial Primary Objective: To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]). Trial Primary Objective: To document the safety profile of the xanomeline TTS.",,https://github.com/OHDSI/CommonDataModel/blob/v5.3.1/OMOP_CDM_v5_3_1.pdf,2015-03-31,2021-06-10,5.3.1,v5.0 22-DEC-20
